Pfizer Animal Health is reminding horse owners of the importance of treating encysted small redworm larvae this autumn.
According to the company, these hidden, dormant parasites can account for up to 90% of the redworm burden in a horse (1). Furthermore, encysted small redworm larvae won't show up in a faecal egg count (FEC). Even if a horse has shown a negative or low count it could still be harbouring several million harmful larvae, hidden within the gut wall (2)
Encysted small redworm are a potential time bomb, with the ability to survive inside a horse for up to two years. They usually 'wake-up' in the late winter or early spring, developing and emerging from the gut wall all at the same time. Such a sudden mass emergence can cause a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate (2). Treating encysted small redworm successfully in the late autumn or early winter is vitally important in order to prevent this serious risk.
Pfizer says that Moxidectin, the key ingredient of EQUEST, is recognised as the only single dose treatment for encysted small redworm. It has been shown to kill the larvae in-situ, without resulting in severe inflammation of the gut wall that other multi-dose treatments may cause (3). In addition, Moxidectin is licensed for persistent activity against small redworm over two weeks, killing larvae ingested as the horse grazes for up to two weeks after treatment.
Ben Gaskell, Pfizer's veterinary advisor said: "A responsible and sustainable worming programme involves good pasture management, regular diagnostic tests and targeted worming, carefully planned using specialist advice. However, it is also vital to remember the danger of encysted small redworm. Even if a horse's FEC is clear, there could still be a significant encysted small redworm burden that must be treated properly every year in late autumn / early winter."
1) Bairden K. et al (2001) Veterinary Record 148, 138-141 2) Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242 3) Steinbach T. et al (2006) Veterinary Parasitology 139, 115‑131
Scientists from the Animal Health Trust, the Wellcome Trust Sanger Institute and the University of St. Andrews have pinpointed the genes which allow the bacteria responsible for strangles to thrive, thereby paving the way for the development of a vaccine.
In the study, which the researchers say was the largest of its kind, 224 samples of Streptococcus equi (S. equi) were procured from horses around the globe to try and find a common bacterial ancestor from which modern strains would have developed. Despite the disease first being described in 1251, the researchers were surprised at the genetic similarity of the samples and identified a total population replacement at the 19th or early 20th century. This corresponds to a period when horses from around the world were brought together in global conflicts including World War I, where an estimated eight million horses died on the battlefield.
Dr Simon Harris from the Wellcome Trust Sanger Institute said: “The mobilisation and mixing of horses in conflicts such as WWI provided perfect conditions for S. equi to thrive. This combined with high mortality rates among the horses and their replacement with young susceptible horses could explain what we see around the world today".
While loss of diversity could be considered detrimental to bacterial populations, S. equi still infects more than 20,000 horses in the UK alone each year. Its success, researchers believe, is due to its ability to persist in some horses for years after they have recovered from strangles, where the bug can evolve to evade the horse’s immune system.
Dr Andrew Waller, Head of Bacteriology at the Animal Health Trust said: “The data we have gathered in this study has enabled us to pinpoint the genes that help the bacteria to persist, spread and thrive in the horse population. This research provides an unprecedented opportunity to reduce the impact of and prevent strangles in future generations of horses.”
The AHT says that the ability of S. equi to adapt to living in a persistent state within its host and still infect new horses mirrors the situation with HIV and the bacteria that causes tuberculosis in humans. Dr Matthew Holden from the Wellcome Trust Sanger Institute and the University of St Andrews said: “Unravelling the complex population dynamics of S. equi sheds new light on the balancing act between acute and persistent infection that is going on in many pathogens. Not only does this collection of whole-genome sequences for S. equi offer hope for an effective strangles vaccine, it also provides us with a useful model for understanding persistent infection in humans.”
Zoetis has announced that Horse & Country TV (Sky Channel 253) will be airing the Vet Essentials episode on worm control in horses from today until 26th March.
The programme, made in association with Zoetis, follows presenter Jenny Rudall on her mission to explore every aspect of worming horses, including how to tackle encysted small redworm. Jenny talks to vet Ben Gaskell from Minster Vets for the low down on worm control, before heading off to the Moredun Research Institute in Scotland to meet parasitology experts Jacqui Matthews and Thomas Tzelos to find out more about the role of faecal worm egg counts, the damage that can be caused by worm burdens and the growing problem of resistance.
Zoetis vet Wendy Talbot said: "The programme should be a big help to vets when it comes to explaining worming to horse owners. They can tell their clients about it and encourage them to watch. It will help educate them about all aspects of worming and specifically about the threat of encysted small redworm at this time of year. This, in turn, should help protect horses against this potentially fatal parasite."
The company is encouraging the profession to help spread the word about the new to clients by email, via Facebook and by word of mouth.
Pfizer Animal Health has launched a dedicated Equine Business Unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Created following the merger with Fort Dodge, the Pfizer Equine Business Unit is headed by Ben Lacey MA Vet MB MRCVS, who has previously held both technical and sales roles at Pfizer. Ben and his team have a brief to offer a breadth of product, support and flexibility not previously available to equine vets.
The product range offered by the Pfizer Equine Business Unit includes the Equest range of parasiticides; the Duvaxyn vaccines for Equine Herpes Virus, West Nile Virus and Rotavirus and products such as Equimidine and Torbugesic. Also offered are existing Pfizer brands such as the Equip vaccine range, the antibiotic Excenel Sterile Powder, the NSAID Rimadyl for Horses and Depo-MedroneV.
Five experienced account managers with a strong track record in the equine sector have been appointed by Pfizer to build relationships with equine vet practices on a regional basis. They are:
South East England Mark BakerWest Midlands, Cheshire, Wales Laurie MayEast Anglia, East Midlands Penny McCannSouth West, South Wales Anna CunninghamThe North, Scotland Alexandra Cox
Ben Lacey said: "Building our new team and combining the highly regarded products offered previously by both Fort Dodge and Pfizer has proved a stimulating process. We've also worked closely with many of our existing practice customers to look at how we can develop the service we provide to them.
"We're now able to offer a product range which I believe is unrivalled in the market and a highly committed team of equine professionals, who share a vision and passion for equine health. We're looking forward to building our business with both existing and new customers in the months ahead."
The webinar will be presented by Dr Abigail McGlennon from the Equine Infectious Disease Surveillance (EIDS) team at the University of Cambridge who will present data from the Surveillance of Equine Strangles (SES) network to provide a detailed overview of strangles diagnoses across the UK.
Abigail will explore recent trends in outbreak reports, the genetic makeup of recent circulating strains and transmission links between UK outbreaks.
By linking research from her own PhD work on S. equi genomics and transmission with preventative strategies, Abigail show how to suggest and implement evidence-based prevention measures to clients.
The webinar will also offer advice on ‘the ates’ preventative measures – vaccinate, isolate, investigate and communicate – and will include information on when horse owners should be vaccinating with Strangvac and an outbreak management vaccination plan using the traffic light ‘green, amber and red’ system.
https://go.dechra.co.uk/preventative_strategies_for_strangles
Horses suffering from neurological conditions similar to those that affect humans could be helped by a breakthrough from stem cell scientists, according to a study published in the journal Stem Cells and Development.
Researchers at the University of Edinburgh's Roslin Institute took skin cells from a young horse and turned them into stem cells using a technique that was originally developed for human cells. The reprogrammed cells are pluripotent, which means they can be induced to become any type of cell in the body. The team used them to create nerve cells in the laboratory and tested whether they were functional by showing that they could transmit nerve signals in a test tube.
The university says horse stem cells have been produced in the laboratory before but this is the first time that scientists have created working cells of a specific type from them. The advance may pave the way for cell therapies that target conditions similar to motor neurone disease.
In addition, the research could also benefit horses affected by grass sickness, a neurological condition that affects around 600 horses a year in the UK. Little is known about the disease, which causes nerve damage throughout the body. It is untreatable and animals with the most severe form usually die or have to be put down.
Dr Xavier Donadeu from the Roslin Institute, an author of the study, said: "Stem cells hold huge therapeutic potential both for people and animals. Our research is an important step towards realising that potential for horses and provides an opportunity to validate stem-cell based therapies before clinical studies in humans."
Congratulations to Merial for a creative initiative to celebrate the 25th birthday of Eqvalan®.
The company made a much needed donation towards the upkeep of the Pewsey White Horse in return for being able to use it as part of Eqvalan's birthday celebration publicity programme for 2008.
The money will be used to restore the protective fencing around the ancient landmark, near Marlborough in Wiltshire.
Merial's Claire Parry- Baggott explains: "There are a number of white horse sites across the UK, many of which are extremely popular visitor destinations. To keep these sites open to the public requires year-round maintenance, often from a small army of volunteers.
"Horse owners have been using Eqvalan to help protect their trusty companions for 25 years, and this initiative will help provide protection of a different kind!
"The idea sprang from the current Eqvalan advertising campaign which celebrates 25 years of worming protection. The result is a fantastic 100 feet replica of our Eqvalan birthday horse, and brand new fencing for the Pewsey White Horse!
"We were delighted to help the Pewsey Council raise funds to preserve the site and hopefully this money will enable the horse to be enjoyed by many for years to come," concludes Claire.
The company now expects the vaccine will not be available until June 2025.
The company apologised for the disruption and inconvenience and says it will provide more information as soon as it becomes available.
For further information contact your Zoetis Account Manager or call Head Office on 0345 300 8034.
"Reasons to be fearful? Rising proportions of positive faecal worm egg counts among UK horses (2007–2023)1" which was conducted in collaboration with Animal Health Vision International, the University of Liverpool and jDATA Pty (Ltd), analysed quarterly surveillance data summaries of FWEC test results that were submitted to the Equine Quarterly Disease Surveillance report (EQDSR) by 36 UK laboratories.
Of these, 18 laboratories provided additional details through a survey on the testing methods adopted.
The researchers say there was considerable variation between laboratories in both the FWEC test methods used and the FWEC positivity thresholds applied to designate a test result as positive for either surveillance reporting or for treatment purposes.
However, the analysis revealed an increase in the proportion of positive FWECs over time, even after accounting for the time of year that testing was conducted, the FWEC positivity threshold used for reporting a sample as positive and the laboratory undertaking the testing.
Researchers say these findings raise questions about targeted treatment strategies, where anthelmintics are administered if FWECs exceed a certain threshold.
If this threshold remains low, the increasing proportion of positive FWECs that were identified would lead to increased use of wormers, potentially accelerating the development of anthelmintic resistance.
This highlights the need to better understand the factors driving rising FWEC positivity rates and if they are a cause for concern.
For example, is this trend leading to increased numbers of horses exceeding the treatment threshold and therefore being recommended for treatment?
The study authors say that the continuation of coordinated efforts to enhance parasite control strategies across the UK equine industry is essential.
The recently available guidelines from the British Equine Veterinary Association (BEVA) and CANTER provide essential resources for vets, pharmacists and RAMAs/SQPs who prescribe equine anthelmintics to optimise parasite control2,3.
References
A new US colic study, published in Equine Veterinary Journal (EVJ), in partnership with the American Association of Equine Practitioners, has identified various risk factors, including delayed faecal output and increasing blood lactate, associated with post-anaesthetic colic.
The study Risk factors associated with gastrointestinal dysfunction in horses undergoing elective procedures under general anaesthesia was conducted by surgeons based at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University, USA.
The authors say that the research should enable vets to implement preventative measures to help reduce incidences of colic in the future.
Gastrointestinal pain has been estimated to occur in 2.8-6% of horses following general anaesthesia for elective procedures, the most common cause being impaction of the large intestine or caecum.
The medical records of 416 horses undergoing general anaesthesia were collected over a two-year period and the potential risk factors were examined. 8.7% of horses were diagnosed with gastrointestinal dysfunction - higher than previous estimates probably because the study included horses requiring treatment for decreased faecal output whereas previous studies did not. Potential risk factors were assessed, including faecal output, which was decreased in 38.9% of cases, blood lactate, position during surgery, rectal temperature and breed of horse.
The results showed that Arabian horses, increasing blood lactate, right lateral recumbency, decreased rectal temperature post-procedure and delayed passage of faeces were significantly associated with an increased risk of gastrointestinal dysfunction.
Diana Hassel, who instigated the study, said: "These findings should help the clinician identify higher risk horses and be proactive about their management in the post-anaesthetic period.
"This may include pre-emptive nasogastric intubation and administration of mineral oil and/or water and electrolytes. Although core temperature control in horses is difficult to achieve in adult horses during surgery, further research into this field may prove beneficial."
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "This study brings obvious and immediate practical benefits for clinicians and the horses under their care. Rigorous monitoring of higher risk surgical cases should lead to a reduction in incidences of post-operative colic, making recovery procedures less difficult and outcomes more favourable."
Vet Stuart Thorne from Fellowes Farm Equine Clinic in Abbots Ripton has praised the work of the charity-run National Foaling Bank after it helped save the life of an orphan three day old filly foal.
Merial has announced that it has joined forces with the Animal Health Trust to hold Equine Flu Awareness Month in April.
Organisers say that the aim is to increase awareness, understanding and virus surveillance of this highly contagious evolving disease.
The AHT’s head of epidemiology and disease surveillance, Dr Richard Newton said: "The creation of Equine Flu Awareness Month is an important step forward for the equine industry. There have been 52 recorded outbreaks of equine influenza in the last two years, and whilst this may sound considerable, we believe it’s actually just the tip of the iceberg."
Equine Flu Awareness Month will integrate the Horserace Betting Levy Board (HBLB) Equine Influenza Surveillance Programme at the AHT with disease outbreak alerts and horse owner education to increase awareness of flu surveillance and vaccination.
The surveillance programme provides ongoing free sampling to all practices registered to the service.
Richard added: "We are fortunate that the HBLB invests in this important scheme which also benefits the industry as a whole. We know that just 40% of the total UK herd is vaccinated, so when you consider that all racehorses and many other competing and performance horses are vaccinated under compulsory rules, that leaves the remainder of the herd even less protected and the total percentage well short of the 70% required in order to prevent an epidemic¹,².
"All isolated viruses in the recent outbreaks are known to be of the Florida Clade 2 sublineage of H3N8 equine influenza, and nearly all outbreaks were in unvaccinated horses or in those whose vaccinations were not up to date³.
"Historical models indicate that an epidemic occurs every 10 to 15 years⁴. The last large outbreak in the UK, which affected vaccinated racehorses, occurred in 2003, so surveillance of virus activity, vaccination and development of vaccines to match the circulating strains are key to preventing another outbreak.
"Many horses that don’t travel are still at risk of equine influenza, but frequently go unvaccinated. These animals are not only at risk of contracting and amplifying virus from their stable-mates that do travel, but are also at risk of airborne infection as equine flu is capable of travelling over a mile as an aerosol on the wind."
Equine Flu Awareness Month will include a focus on practice vaccine amnesties and practice promotional tools with the objective to increase awareness among horse owners, for them to better understand the risks and signs of equine flu.
Louise Radford MRCVS from Merial said: "In addition to the HBLB funded surveillance scheme providing free registration and virus testing, other services include Tell-Tail™ alerts for practices when there is an outbreak in the region, and Tell-Tail™ links to alert clients to outbreaks of equine flu and encourage them to vaccinate."
She added: "Tell-Tail™ Links is a great way to let your clients know when there is an increased risk of equine flu due to an outbreak in the area. When the first broadcast was launched, a text was sent from a practice in Cardiff to 777 horse owners and within 2 weeks, 47 new horses were booked in for a primary vaccination course."
As part of the initiative, Merial is also running a draw to win one of three BEVA vouchers worth up to £1000. To enter, sign up or renew your Tell-Tail™ registration during April 2016 at: www.equinefluawareness.com.
To sign up to the free HBLB Equine Influenza Surveillance Service run by the AHT, visit: www.equiflunet.org.uk
The farriery stream will run all day on Saturday 14 September, with content curated by Dr Simon Curtis who is internationally renowned in the hoof-care world for his remedial farriery textbooks and lectures.
Simon said: “Any historical, perceived divide between science of veterinary medicine and the craft of farriery is no longer in existence.
"The overlap is vast which means it is more essential than ever that vets, nurses and farriers understand each other’s roles in order to maximise their patient outcomes.”
“Farriery isn’t sexy, but it beats everything else for improving soundness.
"It is impossible to maintain or regain soundness without farriery being considered as an integral part of the process.
“The impact good farriery can have on a horse’s ability to tolerate conformational, work-related or other causes of lameness associated pathology is all too often overlooked by all parties, and this should no longer be the case.
"Vets and farriers must work as a team to avoid injury and facilitate recovery wherever possible.”
The sessions will cover things like the importance of trimming, the biomechanical effects of horseshoes, why heels collapse, chronic club foot, digital support and toe-trimming.
The farriery stream is part of 90+ hours of live and on-demand CPD on offer at Congress, with interactive discussions, debates and workshops, and an expanded stream for vet nurses.
https://www.bevacongress.org/programme
BEVA members prices for Congress for all three days are £699 for vets (with concessionary prices available for those in their first three years of graduation or earning less than £25,000), £273 for nurse members for all three days and £300 for farriers and other allied professionals for all three days or £110 for one day.
Practice passes are also available.
The webinar is being presented by Cassie Woods (RVN Cons) CertNCS, Equine Nurse and Partner at Lower House Equine Clinic in Shropshire.
Cassie has a degree in bio-veterinary science and many years experience working in equine and small animal practice.
She regularly lectures for BVNA and BEVA. She is a member of the BEVA equine nurse committee and works closely with the BEVA Trust.
Cassie will share insights and practical strategies to strengthen biosecurity for both clinic and ambulatory teams, and will offer advice and guidance for helping clients to improve their own biosecurity measures.
Horiba's Veterinary specialists will also be available to answer veterinary diagnostics-related questions and share information about the range of pathogen tests the company offers.
https://horiba.link/register-143bbc
Photo: www.depositphotos.com
Langford Veterinary Services, a fully owned subsidiary of the University of Bristol, has announced the opening of a new standing equine magnetic resonance imaging (MRI) facility at the university's equine centre.
The equine MRI facility completes the diagnostic imaging facilities in the School, which include a 16-slice CT scanner for small animals and standing horses, digital radiography, high-resolution fluoroscopy, diagnostic ultrasound, echocardiography and scintigraphy with a high-resolution 1.5 tesla MRI scanner, available seven days a week.
Evita Busschers, Senior Teaching Fellow and orthopaedic surgeon in the equine centre, said: “We are very grateful to the Trustees of the Alborada Trust and the Langford Trust who have provided generous support for the MRI facility. The new imaging facility will enable us to provide an even better and more complete service for our equine patients and completes the diagnostic imaging facilities available at the centre.
“Equine MRI offers the ability to image soft tissue structures and identify soft tissue injuries that cannot be demonstrated with other diagnostic imaging modalities and therefore has major additional value in providing a diagnosis and prognosis in lameness evaluations.”
Miles Littlewort, a trustee from the Alborada Trust added: “Donating the money is the easy bit but ensuring that it has been used where it should be and that it has made the necessary difference is much more challenging. We are so pleased to have had the opportunity to support the Langford Trust and their work to improve animal health and welfare. We are delighted to have attended the opening, to meet the clinicians who will use the magnificent facility and to learn about the clinical research which gives all veterinary surgeons evidence-based information to enhance diagnosis and treatment for all patients.”
Boehringer Ingelheim has launched Care and Connect a free online PPID aftercare service for horse owners, designed to help veterinary practices monitor their PPID case load and streamline the case management process.
The new service is part of Boehringer's 'Talk About Laminitis (TAL)' Awareness campaign.
The company says that PPID is the sixth most frequently encountered disease syndrome affecting equids in the UK1, and the new service should help engage owners and vets post diagnosis, thereby maximising treatment success.
Liz Barrett, equine business manager at Boehringer, said: “PPID is a progressive disease, so it is vital that veterinary surgeons remain at the centre of care, and that horses are monitored carefully following their initial diagnosis. However we recognise the high administrative demand associated with this, and TAL Care and Connect has been designed to reduce this as much as possible.”
TAL Care and Connect will be offered automatically to horse owners who take advantage of this year’s free* ACTH testing scheme, which will be available from July to November. Equine practices can also offer this aftercare service to all owners of previously diagnosed PPID cases.
Owners who join TAL Care and Connect will be able to set up a profile for their horse which allows all their ACTH results to be stored in one place. They will then receive the relevant reminders for follow-up ACTH testing which will make it easier for vets to monitor their patient’s progress over time.
In addition, owners can download an independently-written PPID information pack. Edited by Prof. Catherine McGowan with contributions from Dr Jo Ireland, Prof. Andy Durham, David Rendle and Dr Teresa Hollands, the pack includes advice on monitoring and follow-up ACTH tests, feeding, general care of the PPID patient and the link between laminitis and PPID.
Talk About Laminitis is supported by Redwings, The British Horse Society and World Horse Welfare, and will run from July until the end of October 2015. Horse owners can find out more and obtain their free ACTH voucher code at www.talkaboutlaminitis.co.uk.
For further information contact your local Boehringer territory manager or visit www.talkaboutlaminitis.co.uk.
*Cost of laboratory test
A research project funded by The Horse Trust has found that various types of ocular tumours can be successfully treated with mitomycin C, a cytotoxic antibiotic isolated from a bacterium.
The research concludes that mitomycin C offers a safe and cost effective alternative to current treatment options such as surgery and radiation.
The research project was led by Fernando Malalana, while working as The Horse Trust's Clinical Scholar in Equine Internal Medicine at University of Liverpool. Fernando is now working as a Clinician Teacher in Equine Internal Medicine at the university.
Ocular tumours are more difficult to treat than tumours in other parts of the horse's body due to the risk of damaging the eye. In the study, Malalana investigated the use of mitomycin C in treating ocular squamous cell carcinoma, the most common ocular tumour in horses, and occular sarcoids, skin tumors that frequently affect the eyelids .
Mitomycin C is an antibiotic isolated from a bacterium, Streptomyces caespitosus. It is known to have cytotoxic effects and has been used to treat tumours in horses before, but only in combination with surgery.
Currently, the main method of treating ocular squamous cell carcinoma is by removing the tumour surgically or with radiation. Both treatments are costly and have a number of associated risks. There is also the risk of damage or scarring to the eye.
Fourteen horses with ocular squamous cell carcinoma, three of which were affected bilaterally, were included in the study. Mitomycin C was applied to the conjunctival sac of the affected eye; in some of the cases the treatment was combined with surgery. Malalana found that of the 8 eyes treated with mitomycin C alone, clinical resolution occurred in 6 cases. Of the 9 eyes treated with both surgery and mitomycin C, clinical resolution occurred in 7 cases.
Mitomycin C was also used to treat various types of sarcoids found in the eye. Currently, the most effective treatment for occular sarcoids is radioactive wire. However, radioactive wire treatment is not ideal as it is expensive, only offered in two locations in the UK, and has potential health risks to the vet applying the wire due to exposure to radioactivity.
Six horses and two donkeys with occular sarcoids, including one horse that was affected bilaterally, were treated with mitomycin C, which was injected directly into the tumour. Malalana found that of the nine nodular and fibroplastic occular sarcoids treated with the antibiotic, all were completely cleared. However, the vets did not have good results with verrucous sarcoids.
Malalana said: "The results of this research should offer hope to the owners of horses that have eye tumours. We have already been contacted by vets from across Europe to find out more information about this treatment and hope that it will be offered to more horses with occular tumours in the future".
Vets at the University of Liverpool are now testing the use of mitomycin C on other tumours that are difficult to treat surgically, including melanomas near the horse's anus. So far, two cases have been treated, but it is too early to tell whether treatment has been successful.
Malalana's research has been submitted to Veterinary Ophthalmology journal.
The new resources include:
Celia Marr, chair of BEVA’s infectious disease working group, said: “Equine disease prevention and management are fundamental for responsible equine health, welfare and performance.
“These resources cover the need-to-know information and are all in one easy reverence location on the newly designed infection control page on the BEVA website.”
https://www.beva.org.uk/Resources/Equine-infectious-diseases
The webinars will be available as live podcasts and will also be able to be viewed on demand on the Dechra Academy.
In the strangles webinar, Dave Rendle, Gayle Hallowell and Richard Newton will explore the current landscape of strangles control, focusing on the role of vaccination, testing and quarantine measures.
In the disease prevention webinar, Gayle Hallowell, Dave Rendle, Tamzin Furtado and others will give an insight into chronic disease management and preventative vaccination to improve uptake and optimise treatment outcomes.
Both webinars broadcast from 8pm GMT, with a live Q&A session from 8:45pm, finishing at 9:15pm GMT.
https://membership.elearning.vet/Dechra-equine-medicine-series.
A new scholarship on Equine Emergency and Critical Care has been started at a specialist equine hospital in County Kildare, at the heart of Ireland’s horse-racing district. Anna Hollis is the recipient of the scholarship, which is the first of its kind in Europe.
The scholarship gives her the opportunity to specialize in the field of emergency and critical care and to be Board Certified by the American College of Veterinary Emergency and Critical Care (ACVECC). The scholarship has been funded by a grant from Intervet/Schering-Plough Animal Health.
Anna Hollis (BVet Med, MRCVS) will receive the scholarship, for a duration of two years. Hollis just completed a residency in Medicine at the University of Pennsylvania (New Bolton Center) and already has several publications. She will be under the supervision of Kevin Corley (BVM&S PhD DECEIM DACVIM DACVECC MRCVS), an expert in the field of equine medicine and Board Certified by the ACVECC who is in charge of emergency and critical care at a large equine hospital in the Curragh area of County Kildare, Ireland.
Anna Hollis will be spending several rotation periods in various institutions in Europe and the USA, before taking the board examination for the ACVECC. This is the only equine Emergency and Critical Care residency in the European Union that is recognized by the ACVECC and one of the few in the world taking place at a private institution.
Intervet/Schering-Plough Animal Health is supporting this two-year initiative, “We are very excited to be working with Dr. Corley to establish this scholarship,” said Roberto Ragni-Alunni, Global Technical Manager for the equine business in Intervet/Schering-Plough Animal Health. ”The research offers the possibility to reach a rare level of specialization. This will benefit critically ill horses and help push the boundaries of equine medicine even further.”
The MonitorME project, launched this month, collects antimicrobial usage data from equine practices around the UK, to better understand how antibiotics are used within the sector.
The project is being led by BEVA President Bruce Bladon (pictured) and it will be the main theme at BEVA Congress (10-13 September 2025, ICC Birmingham).
Bruce said: “Growing resistance to antibiotics is a very serious public health crisis, which is why I have chosen it as the overriding theme for my presidential year and for the forthcoming BEVA Congress.
“The World Health Organisation has the usage of veterinary antimicrobials firmly in their sights and the possibility of legislation being implemented to limit our access to these vital drugs is becoming ever more likely.
“It is important that we demonstrate, as a sector, that our usage of antimicrobials is responsible and proportionate, to ensure continued access.
"Taking part in a project like this is, without a doubt, the right thing to do.”
Practices are being asked to submit usage data from their practice management systems (PMS) to the BEVA office, where it will contribute to nationwide reporting of antibiotic use in UK equine practice.
Ideally, they need to record the total mg of each antimicrobial used, together with the number of horses treated last year (in total, not just those treated with antibiotics) and their average weight if available.
The data is analysed and then collated into annual reports, which are published on the BEVA MonitorME webpage.
The 2023 report is now available and will be updated periodically as practices continue to submit their 2023 data.
2024 data collection has started, so equine practices can send their data to antibiotics@beva.org.uk whenever they’re ready.
https://www.beva.org.uk/Resources/Medicines/Antibiotics/MonitorME#aims
https://www.bevacongress.org
Super early bird tickets are available till 28th May.
Rose’s programme recommendations are:
BEVA Congress programme will be embracing the overarching theme of “use it wisely or lose it forever”, chosen by BEVA President Bruce Bladon.
Bruce said: “Antibiotics is an issue which goes so far beyond equine practice and is one of the genuine threats to humanity.
"We must use these precious and finite resource wisely, or, quite reasonably, regulators will prevent us having access to them.
“But this theme resonates further, to the “social licence” which threatens the future of equine sport.
"Rather than platitudes about horse welfare, we now need to show the positive steps we can take to minimise equine injury.
"We need to be developing screening programmes and to be instrumental in safety programmes.
"Otherwise, we may lose equestrian sport forever.”
Individual super early bird BEVA members prices for a three-day pass are £539 for vets for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
Super early bird ends on 28 May 2025.
http://www.bevacongress.org